中西医结合心血管病电子杂志
中西醫結閤心血管病電子雜誌
중서의결합심혈관병전자잡지
Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine (Electronic)
2013年
1期
3-5
,共3页
高脂血症%辛伐他汀%非诺贝特
高脂血癥%辛伐他汀%非諾貝特
고지혈증%신벌타정%비낙패특
hyperlipidemia%simvastatin%fenofibrate
目的：观察辛伐他汀联合非诺贝特治疗混合性高脂血症的效果。方法将126例混合性高脂血症患者随机分为两组63例，观察组每天清晨口服非诺贝特微粒化胶囊100mg，夜间口服辛伐他汀10mg；对照组口服非诺贝特微粒化胶囊100mg，每天2次；疗程均为12周。比较两组治疗前后主要血脂参数的变化率、疗效、达标率及不良反应。结果治疗后观察组与对照组TC、LDL-C、TG、HDL-C水平变化的比较，t值分别为10．7042、10．204、6．0318、3．8144，P值均＜0．01，差异均具有统计学意义。在临床疗效方面，观察组显效32例，占50．8％，有效23例，占32．5％，无效8例，占12．7％，恶化1例，占1．49％；而对照组显效24例，占38．1％，有效16例，占25．4％，无效19例，占30．2％，恶化4例，占6．3％。虽然观察组的各指标在治疗效果上较对照组好，但两组各指标分别比较，差异无统计学意义，P均＞0．05。而总有效率比较，x2＝8．21，P＜0．01，差异具有统计学意义。治疗后两组血脂水平单项达标情况，观察组TC、LDL-C、TG及三项同时达标人数分别为38例、36例、41例和36例，而对照组分别为16例、14例、34例和14例，两组血脂各指标达标情况比较，除TG外，P均＜0．01，差异均具有统计学意义。结论辛伐他汀联合非诺贝特治疗混合性高脂血症效果优于单用非诺贝特，具有临床推广价值。
目的：觀察辛伐他汀聯閤非諾貝特治療混閤性高脂血癥的效果。方法將126例混閤性高脂血癥患者隨機分為兩組63例，觀察組每天清晨口服非諾貝特微粒化膠囊100mg，夜間口服辛伐他汀10mg；對照組口服非諾貝特微粒化膠囊100mg，每天2次；療程均為12週。比較兩組治療前後主要血脂參數的變化率、療效、達標率及不良反應。結果治療後觀察組與對照組TC、LDL-C、TG、HDL-C水平變化的比較，t值分彆為10．7042、10．204、6．0318、3．8144，P值均＜0．01，差異均具有統計學意義。在臨床療效方麵，觀察組顯效32例，佔50．8％，有效23例，佔32．5％，無效8例，佔12．7％，噁化1例，佔1．49％；而對照組顯效24例，佔38．1％，有效16例，佔25．4％，無效19例，佔30．2％，噁化4例，佔6．3％。雖然觀察組的各指標在治療效果上較對照組好，但兩組各指標分彆比較，差異無統計學意義，P均＞0．05。而總有效率比較，x2＝8．21，P＜0．01，差異具有統計學意義。治療後兩組血脂水平單項達標情況，觀察組TC、LDL-C、TG及三項同時達標人數分彆為38例、36例、41例和36例，而對照組分彆為16例、14例、34例和14例，兩組血脂各指標達標情況比較，除TG外，P均＜0．01，差異均具有統計學意義。結論辛伐他汀聯閤非諾貝特治療混閤性高脂血癥效果優于單用非諾貝特，具有臨床推廣價值。
목적：관찰신벌타정연합비낙패특치료혼합성고지혈증적효과。방법장126례혼합성고지혈증환자수궤분위량조63례，관찰조매천청신구복비낙패특미립화효낭100mg，야간구복신벌타정10mg；대조조구복비낙패특미립화효낭100mg，매천2차；료정균위12주。비교량조치료전후주요혈지삼수적변화솔、료효、체표솔급불량반응。결과치료후관찰조여대조조TC、LDL-C、TG、HDL-C수평변화적비교，t치분별위10．7042、10．204、6．0318、3．8144，P치균＜0．01，차이균구유통계학의의。재림상료효방면，관찰조현효32례，점50．8％，유효23례，점32．5％，무효8례，점12．7％，악화1례，점1．49％；이대조조현효24례，점38．1％，유효16례，점25．4％，무효19례，점30．2％，악화4례，점6．3％。수연관찰조적각지표재치료효과상교대조조호，단량조각지표분별비교，차이무통계학의의，P균＞0．05。이총유효솔비교，x2＝8．21，P＜0．01，차이구유통계학의의。치료후량조혈지수평단항체표정황，관찰조TC、LDL-C、TG급삼항동시체표인수분별위38례、36례、41례화36례，이대조조분별위16례、14례、34례화14례，량조혈지각지표체표정황비교，제TG외，P균＜0．01，차이균구유통계학의의。결론신벌타정연합비낙패특치료혼합성고지혈증효과우우단용비낙패특，구유림상추엄개치。
Objective To observe simvastatin fenofibrate treatment of mixed hyperlipidemia effect.Methods 1 26 cases of mixed hyperlipidemia were randomly divided into two groups of 63 cases,the observation group every morning oral micronized fenofibrate capsules 1 00mg,nighttime oral simvastatin 1 0mg;control group was treated with fenofibrate microparticles of capsules 1 00mg,2 times a day;course of treatment was 1 2 weeks.Were compared before and after treatment rate of change of the main lipid parameters,efficacy,compliance rate and adverse reactions.Results After treatment group and control group TC,LDL-C,TG,HDL-C levels in comparison,t values were 1 0.7042, 1 0.204,6.031 8,3.81 44,P<0.01 ,statistically significant differences were.In clinical efficacy observation group 32 cases,accounting for 50. 8%,effective in 23 cases,accounting for 32.5%,8 cases (1 2.7%),worsening one case,accounting for 1 .49%;while the control group that were 24 cases,accounting for 38.1%effective in 1 6 cases,accounting for 25.4%,ineffective in 1 9 cases,accounting for 30.2%,worsening 4 cases (6.3%).Although the indicators in the observation group than the control group on the treatment effect is good,but the two groups were compared each index,the difference was not statistically significant,P>0.05.The total efficiency,x2 =8.21 ,P<0.01 ,statistically significant difference.After treatment,the individual Status lipid levels,the observation group TC,LDL-C,TG,and three at the same time the number of standards were 38 cases,36 cases,41 cases and 36 cases in the control group were 1 6 cases,1 4 cases,34 cases and 1 4 cases,two groups of lipids compared to the situation of the indicators of compliance,in addition to outside TG,P<0.01 ,the differences were statistically signifi-cant.Conclusion simvastatin fenofibrate treatment of mixed hyperlipidemia better than fenofibrate alone has clinical value.
